DNA vaccination with all-trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4+ and CD8+ T-cell activation in an acute promyelocytic leukemia mouse model

Blood

Volumn 115, Issue 3, 2010, Pages 653-656

  Furugaki, Kouichi ^a   Pokorna, Katerina ^a,b   Le Pogam, Carole ^a   Aoki, Masayuki ^a   Reboul, Murielle ^a   Bajzik, Véronique ^a   Krief, Patricia ^a   Janin, Anne ^a   Noguera, Marie Elena ^c   West, Robert ^d   Charron, Dominique ^a   Chomienne, Christine ^a   Pla, Marika ^a   Moins Teisserenc, Hélène ^a   Padua, Rose Ann ^a  

^a INSERM   (France)

^b INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^c UNIVERSITÉ PARIS DIDEROT   (France)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; DNA VACCINE; GAMMA INTERFERON; RETINOIC ACID; ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; DEATH; DEGRANULATION; DNA IMMUNIZATION; ENZYME LINKED IMMUNOSPOT ASSAY; HISTOCOMPATIBILITY COMPLEX; HUMAN; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RELAPSE; REMISSION; SURVIVAL TIME; SURVIVOR; T LYMPHOCYTE ACTIVATION; ANIMAL; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME; TUMOR CELL CULTURE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, CELLULAR; LEUKEMIA, PROMYELOCYTIC, ACUTE; LYMPHOCYTE ACTIVATION; MICE; ONCOGENE PROTEINS, FUSION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRETINOIN; TUMOR CELLS, CULTURED; VACCINES, DNA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77449115351     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-08-109009     Document Type: Article

References (20)

1. John AM, Thomas NS, Mufti GJ, Padua RA. Targeted therapies in myeloid leukemia. Semin Cancer Biol. 2004;14(1):41-62.
2. Lo-Coco F, Ammatuna E, Montesinos P, Sanz MA. Acute promyelocytic leukemia: recent advances in diagnosis and management. Semin Oncol. 2008;35(4):401-409.
3. Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009;113(4):775-783.
4. Brown D, Kogan S, Lagasse E, et al. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 1997;94(6):2551-2556. (Pubitemid 27136913)
5. Padua RA, Larghero J, Robin M, et al. PMLRARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia. Nat Med. 2003;9(11):1413-1417. (Pubitemid 37466192)
6. Robin M, Andreu-Gallien J, Schlageter MH, et al. Frequent antibody production against RARalpha in both APL mice and patients. Blood. 2006; 108(6):1972-1974. (Pubitemid 44395008)
7. Pollock JL, Lane AA, Schrimpf K, Ley TJ. Murine acute promyelocytic leukemia cells can be recognized and cleared in vivo by adaptive immune mechanisms. Haematologica. 2005;90(8):1042-1049. (Pubitemid 41323503)
8. Stephensen CB, Rasooly R, Jiang X, et al. Vitamin A enhances in vitro Th2 development via retinoid X receptor pathway. J Immunol. 2002; 168(9):4495-4503. (Pubitemid 34441352)
9. Dawson HD, Collins G, Pyle R, et al. Direct and indirect effects of retinoic acid on human Th2 cytokine and chemokine expression by human T lymphocytes. BMC Immunol. 2006;7:27.
10. Semba RD, Muhilal Ward BJ, et al. Abnormal Tcell subset proportions in vitamin-A-deficient children. Lancet. 1993;341(8836):5-8.
11. Geissmann F, Revy P, Brousse N, et al. Retinoids regulate survival and antigen presentation by immature dendritic cells. J Exp Med. 2003;198(4): 623-634. (Pubitemid 37040396)
12. Westervelt P, Pollock JL, Oldfather KM, et al. Adaptive immunity cooperates with liposomal alltrans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(14):9468-9473.
13. Padua RACC. Use of animal models for the treatment of leukemias: efficacy of DNA vaccination combined with ATRA. Discovery Med. 2004;4(20): 41-44.
14. Jedema I, van der Werff NM, Barge RM, Willemze R, Falkenburg JH. New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood. 2004;103(7):2677-2682. (Pubitemid 38393024)
15. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003;281(1):65-78.
16. Rubio V, Stuge TB, Singh N, et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med. 2003;9(11):1377-1382. (Pubitemid 37466186)
17. Lollini PL, Cavallo F, Nanni P, Forni G. Vaccines for tumour prevention. Nat Rev Cancer. 2006; 6(3):204-216.
18. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer. 2008; 8(2):108-120.
19. Semba RD, Muhilal Scott AL, et al. Depressed immune response to tetanus in children with vitamin A deficiency. J Nutr. 1992;122(1):101-107.
20. Yoshida Y. Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia. 1993;7(1):144-146. (Pubitemid 23048933)